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ASSESSING THE MAJOR DRIVERS FOR THE INCREASED
HEALTH CARE COSTS ASSOCIATED WITH PROSTATE CANCER
Rahman M1, Weinstein R2, Wilcox M2, Matcho A2, Raghavan B1
1Ortho Clinical Diagnostics, Raritan, NJ, USA, 2PRD USA, Titusville, NJ, USA
OBJECTIVES: This burden of illness study was conducted to assess the 12-month
resource utilization and health care costs, along with the major drivers of those costs,
associated with an incident diagnosis of prostate cancer (PC). METHODS: An analysis
of incident PC patients identiﬁ ed using a claims database, was performed, for 2005, 
2006, and 2007. PC patients and the age and gender matched comparator group (1:4)
for each year, were required to have continuous enrollment in a plan and no prostate 
cancer diagnoses during the 18 months prior to the ﬁ rst diagnosis of prostate cancer
in the year. The PC and comparison groups were each described in terms of their 
health care service use and health care costs, which were compared, using nonpara-
metric Wilcoxon rank-sum tests, with mean values reported here for 2007. RESULTS:
There were 21,520 men diagnosed with PC in 2007, in this database, and we selected 
86,080 controls. The mean health care cost for the men diagnosed with PC was
$19,979 vs. $7,105 for controls; p  0.001. The primary drivers for this nearly triple 
cost difference between the two groups were: hospitalizations ($6,292 vs. $2,375;
p  0.001); radiology tests ($3,014 vs. $348; p  0.001); prescription drugs ($2,293 
vs. $1,439; p  0.001); and laboratory tests ($880 vs. $203; p  0.001). Resource
utilization over the 12-month period showed that the men with PC, when compared
to the control group, had a signiﬁ cantly greater (p  0.001) mean number of hospi-
talizations (0.4 vs. 0.2; p  0.001); radiology tests (10 vs. 2; p  0.001); prescription
drugs (22 vs. 16; p  0.001); and laboratory tests (18 vs. 8; p  0.001). CONCLU-
SIONS: The signiﬁ cantly higher 12-month resource utilization and health care costs
noted in men diagnosed with PC, compared to age and gender matched controls, are 
primarily driven by an increased need for hospitalizations, radiology tests, prescription 
drugs, and laboratory tests.
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HEALTH CARE COSTS IN WOMEN WITH INCIDENT
METASTATIC BREAST CANCER RECEIVING CHEMOTHERAPY 
AS THEIR PRINCIPAL TREATMENT MODALITY
Vera-Llonch M1, Glass A2, Weycker D1, Borker R3, Gao S3, Oster G1
1PAI, Brookline, MA, USA, 2Kaiser Permanente, Northwest Region, Portland, OR, USA, 
3Amgen, Thousand Oaks, CA, USA
OBJECTIVES: To characterize health care resource use and costs in US women with 
incident metastatic breast cancer receiving chemotherapy as their principal treatment
modality. METHODS: Using a retrospective cohort design and a large private health 
insurance claims database (2000–2005), we identiﬁ ed all women initiating chemo-
therapy for incident metastatic breast cancer with no evidence of concomitant or 
subsequent receipt of hormonal therapy or trastuzumab. Health care resource use
(inpatient, outpatient, medications) and costs were tallied on a cumulative basis from 
date of chemotherapy initiation (ie, index date) to date of disenrollment from the 
health plan (in most instances, presumably due to death) or the end of the study period,
whichever occurred ﬁ rst. Study measures were summarized using Kaplan-Meier 
Sample Average (KMSA) method; 95% CIs were generated using nonparametric
bootstrapping. Reimbursed amounts were used as a proxy for costs. RESULTS: The
study population consisted of 820 women; mean (SD) age was 58.4 (12.0) years. Over 
a mean follow-up of 692 days (range: 3 to 2,182), study subjects averaged 1.1 hospital 
admissions, 6.8 inpatient days, and 62.4 physician ofﬁ ce and hospital outpatient visits. 
Mean (95% CI) cumulative total health care costs were $91,400 ($83,804, $99,050)
per patient over this period. Outpatient chemotherapy constituted 24% of total health 
care costs; comparable percentages for inpatient care, outpatient services, and all other 
outpatient pharmacotherapy were 19%, 32%, and 24%, respectively. CONCLU-
SIONS: Health care costs are high in US women with incident metastatic breast cancer 
receiving chemotherapy as their principal treatment modality. This study provides 
important additional information on the cost of treatment of this disease.
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INCIDENCE RATE AND BURDEN OF ILLNESS OF CERVICAL
CANCER IN THE UNITED STATES
Srivastava K1, Rai MK2, Siddiqui MK1, Goyal R2, Chawla A1, Takyar S3, Sharma S1
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OBJECTIVES: To review the incidence rate, mortality and burden of illness in cervical 
cancer in the United States (US). METHODS: The information was retrieved from the
WHO, World Bank, US National Cancer Institute, American Cancer Society, clinical-
trials.gov, Medline and relevant grey literature from 1990 to 2008. We summarized
epidemiological information such as numbers of diagnosed cases and deaths, and
associated burden of illness was the outcome of interest. RESULTS: Cervical cancer
is the second most frequent cancer in women worldwide and the leading cause of 
cancer deaths in the developing world, leading to up to 240,000 deaths per year
(WHO, 2006). There were 11,070 new cases and 3870 estimated deaths in 2008 in
the United States according to SEER data compared to 265,884 cases and 204,406 
deaths in Asia and Africa in 2007 (WHO). The annual economic burden of cervical 
cancer in the US has been estimated in 2004 as US$1.7 bn (National Cancer Institute) 
with direct medical costs estimated as $300–400 m (Insinga et al 2005). The cost of 
treating a single case of localized (early-stage) cervical cancer was estimated in 2000
as US$20,255, while the cost of treating a single case of distant (late-stage) disease 
averaged $36,912 (Chesson et al 2004). Overall annual cervical cancer prevention and 
treatment costs were $26,415 per 1,000 females, with routine cervical cancer screening 
costs were $16,746 per 1,000 females (Insinga et al 2004). The total productivity loss 
in year 2000 due to cervical cancer mortality was estimated at US$1.3 billion (Insinga
2006). The average number of years of life lost per woman who died of cervical cancer 
in the United States was 26.3 years (SEER 2005). CONCLUSIONS: The incidence of 
cervical cancer has decreased in the US in recent years but it still poses a major chal-
lenge to the US and developing countries.
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COSTS OF CARE FOR ELDERLY METASTATIC PROSTATE CANCER
PATIENTS OVER TIME
Obeidat NA1, Onukwugha E2, Bikov K1, Seal B3, Mullins CD2
1University of Maryland, Baltimore, MD, USA, 2University of Maryland School of Pharmacy, 
Baltimore, MD, USA, 3Sanoﬁ -Aventis, Bridgewater, NJ, USA
OBJECTIVES: Costs of all-stage prostate cancer management over time have been
previously examined and are described as U-shaped. There is less information speciﬁ -
cally with regard to late-stage prostate cancer (PC), where patterns of care may differ.
The objective of this study is to examine costs of management of regionally metasta-
sized (i.e. M1) PC patterns. METHODS: SEER-Medicare patients (pts) aged 65 and 
diagnosed with M1 PC between 1994–2002 were selected. The sample was reﬁ ned to 
pts surviving 18 to 36 months post-diagnosis. Mean monthly service (physician, out-
patient facility, hospital, DME, hospice, home health care, and skilled nursing facility
(SNF))-speciﬁ c costs were calculated using Medicare payments to providers. Cost 
patterns at 6 months pre-diagnosis, 6-months post-diagnosis, and 12 months before 
death were plotted. Graphs were stratiﬁ ed by whether or not patients received treat-
ment for PC (radiation, surgery, drug therapy). RESULTS: A total of 1678 pts were 
available for the analysis based on the inclusion criteria. Approximately 88% received 
treatment. A U-shaped cost accrual pattern was observed for treated patients and
patients managed by watchful waiting (WW). A peak in costs was observed at month
of diagnosis, and a higher peak at time of death. The magnitude of costs was higher
among treated patients, with mean costs reaching approximately $7500 at death 
(versus $4000 among patients under WW). Among cost components, hospital services 
contributed the most to cost accrual, more so in untreated patients. Treated patients
cost more than untreated patients with regards to physician services, while untreated 
patients appeared to incur SNF costs more consistently across the observation period. 
CONCLUSIONS: In late-stage prostate cancer, costs of care assume a U-shape, with
the highest costs being incurred at diagnosis and at the end of life. Patterns and com-
ponents of care differed somewhat between treated and untreated patients while hos-
pital services consistently accounted for the most spending.
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THE ECONOMIC BURDEN OF METASTATIC BREAST CANCER
Foster T1, Miller JD1, Boye ME2, Blieden MB1, Ancukiewicz V1, Russell MW1
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OBJECTIVES: Metastatic breast cancer (MBC) is incurable, but survival and quality
of life may be prolonged for years with available therapies; however, costs associated
with MBC and its treatment are not fully deﬁ ned. We conducted this research to
compile and synthesize the published research concerning the health economics of 
MBC. METHODS: We systematically reviewed MEDLINE-indexed, English-
language literature, using keyword searches to identify articles published in the 5 years
before October 2008. We excluded articles related to supportive therapy, early dis
ease, diagnosis, non-economic issues, regions outside North America, Europe or Aus-
tralia, or economic methods. Additional articles were added from searches of non-
MEDLINE-indexed sources such as organization and government websites. RESULTS:
Of 43 articles identiﬁ ed from MEDLINE, 19 were included; an additional 13 articles
and abstracts were added from non-MEDLINE-indexed sources, for a total of 32 arti-
cles and abstracts. No comprehensive study was found which included estimates of the 
total MBC economic burden across all treatment options. Most (7 of 10) analyses of 
the per-patient direct MBC costs originate from the US. The only published national
MBC costs were derived from UK data. Thirteen economic models have been published
showing that numerous treatments are cost-effective, yet generally provide only small 
improvements in survival. Nine published economic models evaluate hormonal thera-
pies; 7 compare letrozole and tamoxifen and generally show letrozole to be cost-
effective. In health technology assessments, trastuzumab, capecitabine, and gemcitabine 
have been judged cost-effective, with inconsistent results for vinorelbine. CONCLU-
SIONS: There is no known recent publication concerning the overall economic burden 
of MBC. However, many publications assess the costs and cost-effectiveness of avail-
able treatments. Models show that some of these treatments, most notably letrozole,
are cost-effective. More MBC economic evaluations should be published to better 
inform the use of new treatment modalities in a variety of health care settings.
PCN62
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OBJECTIVES: Head and neck cancer (HNC) is the sixth most common neoplasm in 
the U.S.; approximately $3.2 billion are spent annually for treatment. The projected 
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average Medicare payment per individual in the ﬁ rst year following diagnosis is
$18,000 in year 2007. However, limited information is available regarding cost expen-
diture in commercial managed care plans. The purpose of this study was to report the
ﬁ rst year per patient cost expenditure after HNC diagnosis among commercially
insured lives. METHODS: A cross-sectional study was performed using data from a 
large U.S. commercial managed care claims database. Adult patients (q18 years)
diagnosed with HNC (based on ICD-9-CM codes) between January 1, 2006 to 
December 31, 2006 (index-period) without previous HNC diagnosis 12 months prior
to index date (ﬁ rst date of HNC diagnosis) were identiﬁ ed. At 12 months post index, 
total health care costs were extracted from medical claims and summarized at per 
patient level. RESULTS: 6,570 subjects were identiﬁ ed. The average age was 61 years
(o14.9) and 44% (n  2869) were females. Midwest (31%) and east (31%) regions 
had a higher (p  .01) representation, compared to south (20%) and west (18%). The
5 most common HNC sites constituted 70% of total diagnosis and consisted of 
unspeciﬁ ed HNC sites (24%; n  1588), lymph nodes (15%; n  1010), larynx (14%; 
n  898), connective and soft tissues (9%; n  579), and tongue (9%; n  507). Com-
monly utilized service types were physician (99%; n  6,486), other outpatient ancil-
lary/surgical (99%; n  6,474) and laboratory/diagnostic (90%; n  5,888). Subjects
had frequent visits to general practitioners (53%; n  3,509), internal medicine doctors 
(38%; n  2,523), and otolaryngologists (35%; n  2,291). Total average and median
health care cost per patient post HCN diagnosis were $29,608 (o77,500) and $7,347, 
respectively. CONCLUSIONS: This study found that the annual cost associated with 
HNC is higher in the commercial managed care population compared with what has 
been reported in the literature for Medicare expenditure.
PCN63
DIFFERENT TREATMENT PATTERNS COSTS IN METASTATIC 
BREAST CANCER (MBC) EXPOSED TO ANTHRACYCLINHES AND
TAXANES (AT) IN 3 DIFFERENT MEXICAN PUBLIC HOSPITALS
Juarez-Garcia A1, Hernandez-Rivera G2, Gómez-Roel X2, Uc-Coyoc R1, Rangel S1, 
Vargas-Valencia JJ3, Martínez-Fonseca J3, Donato BM4, Litalien G4
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OBJECTIVES: In Mexico, breast cancer is the second cause of cancer mortality among 
females. For MBC patients resistant to AT, there are limited treatment options. There
is a scarcity of data regarding clinical management of this population and on the
treatment costs at this stage of the disease. The objective of this study was to estimate 
the cost of treatment patterns of care for MBC patients exposed to (AT) in the Mexican 
public health care sector. METHODS: Through medical chart review a retrospective 
cohort of adult female advanced breast cancer patients resistant to AT was con-
structed. The period was January 2004 to December 2007. Target population data 
ﬁ les were obtained from 600 patients out of 3 tertiary public hospitals in México. 
Treatments reviewed included surgery, radiation, hormonal therapy and cytotoxic
drug therapy RESULTS: Cytotoxic drug therapy was the treatment consuming the 
majority of resources (around 80% of total budget). Capecitabine, vinorelbine, ciclo-
phosfamide were the most common prescribed agents. Clinical drug therapy manage-
ment of the disease was notably different among the three hospitals in the sample. 
This difference translated into a disparity of prescription costs among the sites, ranging 
from US$6700 to $2824 for 1st treatment. Further research is needed to explain this 
variety of treatment patterns, however an initial query based on expert opinion sug-
gests that budget limitation among the hospitals is one of the main reasons. CONCLU-
SIONS: Chemotherapy treatment patterns and costs vary among the different 
hospitals. This ﬁ nding highlights a lack of standardized care for patients among hos-
pitals and suggests that differences are not only a reﬂ ection of scarcety of scientiﬁ c 
data and diversity of prescription preferences among physicians but also of economic
restrictions. Ultimately, there is a clear unmet medical need that needs to be addressed
through evidence based medicine alternatives that support efﬁ cacy and cost effective-
ness treatments.
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THE ECONOMIC BURDEN ASSOCIATED WITH METASTATIC 
COLORECTAL CANCER
Long SR1, Foley KA2, Wang PF3, Barber B3, Zhao Z3
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OBJECTIVES: To estimate total costs and assess primary cost drivers of treating newly 
diagnosed metastatic colorectal cancer (mCRC) after the introduction of biologic 
therapies. METHODS: Using a large claims database of a US nationally commercially
insured population, patients with newly diagnosed mCRC were identiﬁ ed from 2004
to 2006. Patients were followed from initial mCRC diagnosis to either death, disenroll-
ment, or December 31, 2006. Using methods from published literature, the follow-up
period for each patient was divided into three phases: diagnostic, treatment, and death. 
Average monthly costs for the three phases of disease were identiﬁ ed and asssigned as
inpatient, outpatient, emergency room (ER), or medication-related costs (including
chemotherapy and biologic agents). RESULTS: A total of 2322 newly diagnosed 
mCRC patients were identiﬁ ed. Outpatient care was the cost driver during the diag-
nostic (42.6%) and treatment (51.7%) phases. Inpatient care represented 39% of costs 
in the diagnostic phase largely due to surgical resection procedures (88.5%). Inpatient 
care was also the cost driver in the death phase (50.7%). Chemotherapies and biolog-
ics represented 15.6% and 16.2% of costs in the treatment phase; and 12.1% and 
11.7% of total costs across all phases of disease, respectively. CONCLUSIONS:
Inpatient and outpatient care were the key cost drivers in the medical management of 
mCRC. Biologics represented 16.2% of treatment phase costs and 11.7% of all costs 
incurred by mCRC patients across all phases of disease.
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COST OF FIRST LINE METASTATIC COLON CANCER
CHEMOTHERAPIES IN HUNGARY
Jozsa G
University of West Hungary, Sopron, Hungary
OBJECTIVES: In Hungary, resources for anti-cancer chemotherapies are allocated 
from central budget, based on DRG accounts. The goal of current research was 
to investigate annual expenditures of ﬁ rst line chemotherapy protocols of metastatic 
colon cancer of Hungarian patients, especially the contribution of monoclonal 
antibodies. METHODS: A total of 1496 patients’ cost data have been collected.
Cost analysis of ﬁ rst line chemotherapy protocols has been conducted from the per-
spective of payer. Irinotecan, cetuximab, bevacizumab, capecitabine and oxaliplatin
containing regimens have been analysed for 12 consecutive months. RESULTS: Total 
expenditure of ﬁ rst line colon cancer chemotherapies was US$18.8 million for 12 
consecutive months. Average cost per patient was US$12,539 for the investigated
period. The share of patients, who have been treated by monoclonal antibodies con-
taining regimens was 16.8%, while cost of biologicals contributed 35% of total ﬁ rst 
line chemotherapies. CONCLUSIONS: The contribution of monoclonal antibodies
was relatively low in terms of treated patients in ﬁ rst line chemotherapy of colon
cancer. Furthermore, average duration of all chemotherapies were lower than reported 
in clinical trials, resulting suboptimal administration and cumulative dose of anti-
cancer compounds.
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OBJECTIVES: Costs associated with anthracycline-induced cardiotoxic events 
(CE) are not known. To compare cost associated with CE among three cohort
groups: anthracycline-containing-chemotherapy (ACC), no-anthracycline-containing-
chemotherapy (NACC), and no-chemotherapy (control) groups within a U.S. managed
care setting. METHODS: A retrospective cohort study was designed. Adult females
(q18) diagnosed with breast cancer between January 1, 2002 to December 31, 2005 
(index-period) were identiﬁ ed. Subjects with previous CE, breast cancer diagnosis, or 
anthracycline-use 12-months prior to index date were excluded. Index date was 
deﬁ ned as the ﬁ rst claim date for chemotherapy for ACC and NACC cohorts, and the
ﬁ rst non-chemotherapy medication claim date for controls. ACC and NACC were 
matched to controls by month of index date and year of birth. Total health care costs 
were extracted from medical and pharmacy claims and summarized at per patient per
year level. Cost of subjects developed CE were extracted from medical and pharmacy 
claims and were adjusted by using a gamma distributed generalized linear model with 
a log link function. RESULTS: A total of 21,106 subjects were classiﬁ ed as ACC (n 
 3,428), NACC (n  7,125) and controls (n  10,553). NACC cohort was signiﬁ cantly 
(p  .01) older (62 years o 12.5) compared to ACC (53 o 9.7) or control cohorts (59
o 12.5). ACC cohort had a higher (p  .01) degree of comorbidity, (1.8 o 0.8) com-
pared to NACC (1.6 o 0.9) or control (1.3 o 0.8) as measured by Charlson comorbid-
ity-index. At month 12 post index-date, 14% (n  485) of ACC and 5% (n  381) of 
NACC had CE compared to 3% (n  310) of controls. At 12 month post index, the 
unadjusted mean total health care costs per patient were $59,287, $20,528 and
$11,600, respectively. The adjusted total health care costs for subjects developed CE 
were $45,304,951, $17,727,884 and $11,591,263 for ACC, NACC and controls,
respectively. (p  .01). CONCLUSIONS: Health care cost for the ACC cohort was 
signiﬁ cantly higher than the NACC or controls cohorts.
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THE COST OF WAITING: ECONOMIC BENEFIT OF REDUCING
WAITING TIMES FOR EARLY BREAST CANCER RADIOTHERAPY
Cromwell IA, Johnson A, Mackillop W
Queen’s University, Kingston, ON, Canada
OBJECTIVES: The purpose of this study is to determine the economic beneﬁ t,
if any, of reducing waiting from the perspective of the Ontario health care system.
METHODS: An investigation in the Canadian scientiﬁ c and economics literature 
was conducted to determine the costs of assessment, diagnosis, treatment and 
follow-up of patients receiving care for a local recurrence. The risks associated 
with having a local recurrence, metastatic disease and terminal disease were also 
determined from the literature. The resulting cost of treatment was weighted according
to the risk of each health event, and by the associated risk of recurrence due to radio-
therapy delay. RESULTS: The cost of treating a recurrence, weighted according to risk
of progression to more severe disease, was approximately $36,000 within the model.
The associated incremental cost savings per week of waiting reduction was $72.49. 
Sensitivity analysis was conducted around the estimate. CONCLUSIONS: The cost 
savings associated with avoiding one breast cancer recurrence is approximately
$36,000 from the perspective of the health care system. Reducing waiting for radio-
therapy by one week may save the health care system $72 per patient in downstream
